Scientists have reported a new approach to treating lung cancer with inhaled nanoparticles developed at Wake Forest School of Medicine, USA.
In this proof of concept study, Dawen Zhao, M.D., Ph.D., associate professor of biomedical engineering at Wake Forest School of Medicine, used a mouse model to determine if metastatic lung tumours responded to an inhalable nanoparticle-immunotherapy system combined with the radiation therapy that is commonly used to treat lung cancer.
The study is published in the current issue of Nature Communications.
Lung cancer is the second most common cancer and the leading cause of cancer death among both men and women.
More people die of lung cancer than of colon, breast and prostate cancers combined.
Although immunotherapy is promising, it currently works in less than 20% of patients with lung cancer.
Significant clinical evidence suggests that at the time of diagnosis most patients’ tumours are poorly infiltrated by immune cells.
This “cold” immune environment in tumours prevents the body’s immune system from recognising and eliminating the tumour cells.
Overcoming this immunosuppressive tumour environment to attack the cancer efficiently is currently an area of great interest in the scientific community, Zhao said.
Previous approaches have involved direct injection of immunomodulators into tumours to boost their immune response.
However, this approach is generally limited to surface and easily-accessed tumours, and can become less effective if repeated injections are needed to sustain immune response.
“The goal of our research was to develop a novel means to convert cold tumours to hot, immune-responsive tumours,” Zhao said.
“We wanted it to be non-invasive without needle injection, able to access multiple lung tumours at a time, and be safe for repeated use. We were hoping that this new approach would boost the body’s immune system to more effectively fight lung cancer.”
The nanoparticle-immunotherapy system that Zhao and his team developed delivered immunostimulants via inhalation to a mouse model of metastatic lung cancer.
The immunostimulant-loaded nanoparticle which, when deposited in the lung air sacs, were taken up by one specific type of immune cells, called antigen-presenting cells (APC).
The immunostimulant, cGAMP, in the nanoparticle was then released inside the cell, where stimulation of a particular immune pathway (STING) activated the APC cell, which is a critical step to induce systemic immune response.
The team also showed that combining the nanoparticle inhalation with radiation applied to a portion of one lung led to regression of tumours in both lungs and prolonged survival of the mice.
In addition, the team reported that it completely eliminated lung tumours in some of the mice.
Through mechanistic studies the team then confirmed that the inhalation system converted those initially cold tumours in both lungs to hot tumours favourable for robust anti-cancer immunity.
Zhao’s inhalable immunotherapy presents several key advantages to previous methods, especially the ability to access deep-seated lung tumours because the nanoparticulate-carrying aerosol was designed to reach all parts of the lung, and the feasibility of repeated treatment by using a non-irritating aerosol formulation.
The treatment was shown to be well tolerated and safe without causing adverse immune-related distress in the mice.
The Wake Forest School of Medicine researchers have filed a provisional patent application for the inhalable nanoparticle-immunotherapy system.